UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

l	OMB Number:	3235-0287	
	Estimated average burden		
	hours per response:	0.5	l

Check this box if no longer subject to Section 16. Form 4 or Form 5	
obligations may continue. See nstruction 1(b).	

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Gordon Stephen			2. Issuer Name and Ticker or Trading Symbol <u>TransMedics Group, Inc.</u> [TMDX]		tionship of Reporting Person all applicable) Director	10% Owner
	st) (First) (Middle) O TRANSMEDICS GROUP, INC.) MINUTEMAN ROAD		3. Date of Earliest Transaction (Month/Day/Year) 05/06/2019	X	Officer (give title below) Chief Financial C	Other (specify below) Officer
		01810 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv X	idual or Joint/Group Filing (C Form filed by One Reporti Form filed by More than C	ng Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311. 4)
Common Stock	05/06/2019		J ⁽¹⁾		100,000	D	(1)	0	D	
Common Stock	05/06/2019		J ⁽¹⁾		28,571	A	(1)	28,571	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Stock Option (Right to Buy)	\$0.1 9 ⁽³⁾	05/06/2019		J ⁽³⁾			200,000 ⁽³⁾	(2)	04/01/2025	Common Stock	57,142	(3)	0	D	
Stock Option (Right to Buy)	\$0.67 ⁽³⁾	05/06/2019		J ⁽³⁾		57,142 ⁽³⁾		(2)	04/01/2025	Common Stock	57,142	(3)	57,142	D	
Stock Option (Right to Buy)	\$0.63 ⁽³⁾	05/06/2019		J ⁽³⁾			142,551 ⁽³⁾	(4)	06/22/2027	Common Stock	40,728	(3)	0	D	
Stock Option (Right to Buy)	\$2.21 ⁽³⁾	05/06/2019		J ⁽³⁾		40,728 ⁽³⁾		(4)	06/22/2027	Common Stock	40,728	(3)	40,728	D	

Explanation of Responses:

1. The Common Stock reported herein as being disposed of is common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), such common stock of TransMedics, Inc. was converted into shares of common stock of the Issuer on a 3.5-for-one basis.

2. The option vested 25% on the first anniversary of the vesting commencement date, March 23, 2015, and at a rate of 2.0833% each month thereafter until the option is fully vested on the fourth anniversary of the vesting date

3. The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

4. The options vests at a rate of 2.0833% of the total number shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, June 22, 2017.

Remarks:



** Signature of Reporting Person

05/06/2019

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.